Hub : Traits :

Triglycerides

509 significantly associated models · 138 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	39328203	40737589	2	1	5.5e-08	7.0e-07	4.4e-01	98	PABPC4
2	1	61510619	64021096	4	1	3.7e-42	1.2e-42	1.0e+00	100	USP1
3	1	229499636	231115887	1	1	8.3e-14	8.1e-14	1.0e+00	100	GALNT2
4	2	20062043	21958745	2	3	1.0e-09	1.4e-45	5.5e-34	26	APOB HS1BP3
5	2	26592429	29344127	32	10	2.3e-135	5.7e-133	1.0e+00	100	ATRAID C2orf28 CAD CGREF1 FNDC4 NRBP1 PPM1G RP11-373D23.3 SNX17 ZNF513
6	2	164657815	166170073	1	1	4.9e-08	1.6e-10	1.2e-05	53	GRB14
7	4	3054017	3688660	1	1	2.9e-08	9.0e-06	3.2e-01	95	RGS12
8	4	86819377	89140356	7	2	5.3e-10	3.9e-11	1.3e-02	86	PTPN13 RP11-529H2.2
9	7	71652312	73843516	10	6	6.3e-67	1.2e-58	1.0e+00	100	BCL7B MLXIPL NSUN5 TBL2
10	8	10932868	12751157	4	1	4.6e-09	3.7e-07	8.7e-01	100	NEIL2
11	8	18003897	18505600	1	1	1.7e-11	4.6e-14	4.9e-04	79	NAT2
12	8	19064892	20858217	2	4	2.1e-105	1.5e-115	1.5e-06	96	LPL LZTS1
13	10	64195778	66034105	3	1	5.2e-12	7.6e-12	1.0e+00	100	NRBF2
14	11	60549966	62346131	7	1	8.6e-25	5.4e-24	2.1e-01	98	FADS3
15	11	115953897	117800682	7	8	9.7e-138	8.9e-122	NaN	NaN	BUD13 PAFAH1B2 PCSK7 SIDT2 ZNF259
16	12	57249600	58677299	2	1	4.9e-09	6.6e-10	4.7e-02	90	INHBC
17	12	123716376	125270773	6	1	3.0e-09	1.6e-08	4.5e-01	98	RP11-380L11.3
18	15	42927984	44310790	3	2	1.8e-08	3.3e-11	1.7e-04	68	CKMT1A LCMT2
19	16	30347731	31860399	9	1	8.2e-09	1.2e-07	5.6e-01	99	BCKDK
20	16	56330832	57810318	3	1	5.6e-14	1.1e-12	1.0e+00	100	CETP
21	19	18333894	20843876	12	1	2.0e-26	1.6e-29	1.1e-04	88	ATP13A1
22	19	45114009	45695738	6	3	1.0e-19	1.1e-30	6.4e-08	78	APOC1 APOC4 TOMM40
23	20	32594714	34109427	2	1	8.3e-08	7.8e-08	2.3e-01	95	TP53INP2
24	20	43766067	45235570	7	4	2.3e-11	4.7e-18	5.0e-01	99	PLTP ZSWIM1
25	22	37781874	39300936	2	1	1.7e-07	3.8e-08	5.4e-02	88	BAIAP2L2

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.54	2	0	0.0	0.00	1.0e+00	FNDC4 TP53INP2
Bipolar Disorder or Schizophrenia	1.14	1	1	2.2	0.00	1.0e+00	CGREF1
Intelligence (Savage-Jansen 2018)	1.10	2	0	0.0	0.00	1.0e+00	FADS3 NRBF2
Neuroticism (Nagel 2018)	0.91	2	1	2.2	0.00	1.0e+00	BCKDK TP53INP2
Schizophrenia (2018)	1.04	1	0	0.0	0.00	1.0e+00	CGREF1
Schizophrenia vs Biploar Disorder	1.89	1	0	0.0	0.00	1.0e+00	FNDC4
Worry (Nagel 2018)	1.13	2	0	0.0	0.00	1.0e+00	BCKDK TP53INP2
Alzheimer’s Disease (in mother)	6.54	3	3	6.7	0.00	1.0e+00	APOC1 APOC4 TOMM40
Alzheimer’s Disease (in father)	3.67	3	2	4.4	0.00	1.0e+00	APOC1 APOC4 TOMM40
Alzheimer’s Disease (including proxy)	14.24	4	3	6.7	0.61	3.9e-01	APOC1 APOC4 BCKDK TOMM40
Crohns Disease (2017)	2.15	3	2	4.4	0.00	1.0e+00	FADS3 FNDC4 RP11-373D23.3
Irritable Bowel Disease (IBD)	1.60	2	2	4.4	0.00	1.0e+00	FNDC4 RP11-373D23.3
Reaction Time	1.03	1	0	0.0	0.00	1.0e+00	RP11-380L11.3
Verbal and Numeric Reasoning (VNR)	1.22	1	0	0.0	0.00	1.0e+00	FADS3
Breast Cancer	1.41	1	1	2.2	0.00	1.0e+00	BAIAP2L2
Bipolar Disorder (2011)	2.59	1	0	0.0	0.00	1.0e+00	PLTP
Body Mass Index (BMI) (2010)	1.66	1	0	0.0	0.00	1.0e+00	CKMT1A
Coronary Artery Disease (CAD)	3.06	3	1	2.2	0.00	1.0e+00	LPL RP11-380L11.3 ZNF259
Crohns Disease (2012)	1.87	3	0	0.0	0.00	1.0e+00	FADS3 RP11-373D23.3 USP1
Mean Putamen Volume	1.57	1	0	0.0	0.00	1.0e+00	TP53INP2
Fasting Glucose	5.22	5	5	11.1	-0.97	7.6e-03	CGREF1 FADS3 FNDC4 NRBP1 PPM1G
HDL Cholesterol	42.88	19	13	28.9	-0.78	2.5e-06	APOB APOC1 BCL7B BUD13 CETP FADS3 GALNT2 GRB14 HS1BP3 INHBC LPL LZTS1 MLXIPL NRBF2 PABPC4 PLTP RP11-380L11.3 ZNF259 ZSWIM1
LDL Cholesterol	13.89	14	10	22.2	0.58	2.4e-02	APOB APOC1 APOC4 ATP13A1 BUD13 CETP FADS3 FNDC4 HS1BP3 PAFAH1B2 PCSK7 RGS12 USP1 ZNF259
Neuroticism (2016)	1.33	1	0	0.0	0.00	1.0e+00	NEIL2
Rheumatoid Arthritis	1.07	1	0	0.0	0.00	1.0e+00	NAT2
Schizophrenia (2014)	0.93	1	0	0.0	0.00	1.0e+00	CGREF1
Blood Eosinophil Count	1.62	7	6	13.3	-0.77	8.7e-03	APOC1 APOC4 BCKDK FADS3 LPL PAFAH1B2 ZNF259
Blood Platelet Count	6.51	31	24	53.3	0.10	5.5e-01	APOC1 APOC4 ATP13A1 ATRAID BCL7B BUD13 C2orf28 CAD CGREF1 CKMT1A FADS3 FNDC4 GALNT2 INHBC LCMT2 MLXIPL NRBF2 NRBP1 PABPC4 PAFAH1B2 PCSK7 PLTP PPM1G PTPN13 RGS12 RP11-380L11.3 RP11-529H2.2 SIDT2 SNX17 USP1 ZNF259
Blood Red Count	1.89	18	11	24.4	-0.22	3.7e-01	ATP13A1 BAIAP2L2 BCKDK CKMT1A FADS3 FNDC4 GALNT2 GRB14 HS1BP3 INHBC LCMT2 NEIL2 NRBF2 PCSK7 PLTP RP11-380L11.3 RP11-529H2.2 ZSWIM1
Blood White Count	3.63	19	14	31.1	0.64	2.4e-03	APOC1 ATP13A1 ATRAID BCKDK BCL7B C2orf28 CAD FADS3 FNDC4 MLXIPL NRBF2 NRBP1 PAFAH1B2 PPM1G RP11-373D23.3 RP11-380L11.3 RP11-529H2.2 SNX17 TOMM40
Heel T-Score	1.15	8	5	11.1	0.39	3.0e-01	ATP13A1 BCKDK FADS3 PLTP PTPN13 RP11-380L11.3 RP11-529H2.2 ZSWIM1
BMI	1.61	10	5	11.1	-0.08	8.4e-01	BCKDK FNDC4 GALNT2 GRB14 MLXIPL NRBF2 PABPC4 RGS12 RP11-380L11.3 TP53INP2
Height	1.43	27	16	35.6	-0.64	1.6e-04	APOC1 APOC4 ATP13A1 ATRAID BAIAP2L2 BCL7B C2orf28 CAD FADS3 FNDC4 GALNT2 LPL MLXIPL NRBF2 NRBP1 NSUN5 PABPC4 PLTP PPM1G RGS12 RP11-373D23.3 RP11-529H2.2 SNX17 TBL2 TP53INP2 ZNF259 ZSWIM1
Waist Hip Ratio (WHR)	5.04	12	4	8.9	0.45	1.3e-01	APOC1 ATP13A1 BCL7B BUD13 CGREF1 GRB14 LPL MLXIPL NSUN5 PABPC4 PAFAH1B2 RP11-380L11.3
Systolic Blood Pressure	1.45	12	2	4.4	0.80	9.1e-04	APOC1 ATRAID FNDC4 GRB14 NRBF2 NRBP1 PAFAH1B2 PCSK7 PPM1G RGS12 RP11-373D23.3 SIDT2
Allergy or Eczema	1.43	2	1	2.2	0.00	1.0e+00	FNDC4 RP11-373D23.3
Cardiovascular Disease	4.47	17	9	20.0	0.89	3.0e-08	APOB BCKDK BCL7B BUD13 FNDC4 LPL MLXIPL NAT2 NRBF2 PABPC4 PAFAH1B2 PCSK7 PPM1G RGS12 SIDT2 USP1 ZNF259
Hypothyroidism (self reported)	1.30	3	2	4.4	0.00	1.0e+00	FADS3 PTPN13 RGS12
Respiratory disease	1.53	2	1	2.2	0.00	1.0e+00	FADS3 PABPC4
Type 2 Diabetes (T2D) (2018)	3.54	9	3	6.7	-0.43	2.5e-01	ATP13A1 FNDC4 GRB14 LPL NRBP1 PABPC4 PPM1G RP11-380L11.3 SNX17
Lung FEV1/FVC ratio	1.18	4	2	4.4	0.49	5.1e-01	BCKDK BCL7B NRBF2 PABPC4
Lung FVC	1.03	7	2	4.4	-0.42	3.5e-01	BCKDK NRBF2 PABPC4 RGS12 SIDT2 TOMM40 TP53INP2
Neuroticism	1.08	2	0	0.0	0.00	1.0e+00	BCKDK TP53INP2
Hair Pigment	2.65	15	5	11.1	0.05	8.5e-01	ATRAID BCL7B FADS3 FNDC4 HS1BP3 INHBC NRBP1 PABPC4 PAFAH1B2 PPM1G RP11-373D23.3 SIDT2 SNX17 TOMM40 TP53INP2
Tanning	4.91	6	3	6.7	0.05	9.3e-01	BAIAP2L2 FNDC4 MLXIPL NRBP1 RP11-373D23.3 TP53INP2
Hand grip strength (left)	1.18	2	0	0.0	0.00	1.0e+00	BCKDK RP11-380L11.3
Number of treatments/medications taken	2.21	3	0	0.0	0.00	1.0e+00	FADS3 FNDC4 NRBP1
Relative age of first facial hair	1.66	3	1	2.2	0.00	1.0e+00	FNDC4 NRBF2 TP53INP2
Systolic blood pressure, automated reading	1.11	1	1	2.2	0.00	1.0e+00	NEIL2
Angina	2.29	1	0	0.0	0.00	1.0e+00	LPL
Supplements: Zinc	1.50	1	0	0.0	0.00	1.0e+00	NRBF2
Medication: Metformin	2.64	3	1	2.2	0.00	1.0e+00	APOC1 FNDC4 LPL
Diabetes (father)	1.63	1	0	0.0	0.00	1.0e+00	FNDC4
Diabetes (mother)	1.89	1	0	0.0	0.00	1.0e+00	ATP13A1
Impedance of leg (right)	1.77	12	5	11.1	0.31	3.3e-01	ATP13A1 BCKDK BCL7B CKMT1A FNDC4 LCMT2 MLXIPL NEIL2 PABPC4 PTPN13 TP53INP2 ZNF513
Leg fat-free mass (left)	2.25	13	7	15.6	-0.49	9.0e-02	ATP13A1 BAIAP2L2 BCKDK BCL7B FNDC4 LCMT2 MLXIPL NRBP1 NSUN5 PABPC4 PTPN13 RP11-373D23.3 TP53INP2
Trunk fat percentage	2.21	7	4	8.9	-0.43	3.4e-01	BAIAP2L2 BCKDK CGREF1 GALNT2 GRB14 PABPC4 RP11-380L11.3
Hand grip strength (right)	1.19	2	0	0.0	0.00	1.0e+00	RP11-380L11.3 TP53INP2
Average weekly fortified wine intake	1.20	1	0	0.0	0.00	1.0e+00	TOMM40
Frequency of unenthusiasm / disinterest in last 2 weeks	1.85	1	0	0.0	0.00	1.0e+00	BCL7B
Relative age voice broke	1.40	1	0	0.0	0.00	1.0e+00	TP53INP2
Age when periods started (menarche)	1.37	2	1	2.2	0.00	1.0e+00	NRBF2 ZNF513
Heel bone mineral density (BMD) T-score, automated (left)	1.40	4	1	2.2	0.54	4.6e-01	FADS3 NEIL2 RP11-380L11.3 RP11-529H2.2
High blood pressure	1.65	3	2	4.4	0.00	1.0e+00	BCKDK NEIL2 NRBF2
Hayfever, allergic rhinitis or eczema	1.73	2	1	2.2	0.00	1.0e+00	RP11-373D23.3 SNX17
Medication: Levothyroxine sodium	0.99	1	1	2.2	0.00	1.0e+00	FADS3
Sitting height	1.82	11	5	11.1	-0.54	6.8e-02	ATP13A1 BAIAP2L2 BCL7B FADS3 FNDC4 MLXIPL NRBP1 PABPC4 PPM1G RGS12 TP53INP2
Body mass index (BMI)	1.65	8	2	4.4	-0.16	7.0e-01	BCKDK CKMT1A FNDC4 GALNT2 GRB14 NEIL2 NRBF2 RP11-380L11.3
Impedance of leg (left)	1.72	11	5	11.1	0.30	3.7e-01	ATP13A1 BCKDK CKMT1A FNDC4 LCMT2 MLXIPL NEIL2 PABPC4 PTPN13 TP53INP2 ZNF513
Leg predicted mass (left)	2.25	14	7	15.6	-0.50	7.1e-02	ATP13A1 BAIAP2L2 BCKDK BCL7B CKMT1A FNDC4 LCMT2 MLXIPL NRBP1 NSUN5 PABPC4 PTPN13 RP11-373D23.3 TP53INP2
Trunk fat mass	1.97	7	4	8.9	-0.16	7.3e-01	BAIAP2L2 BCKDK CGREF1 GRB14 PABPC4 RP11-380L11.3 TP53INP2
Waist circumference	1.48	4	1	2.2	-0.72	2.8e-01	BCKDK FNDC4 PABPC4 RP11-373D23.3
Number of incorrect matches in round	1.56	2	1	2.2	0.00	1.0e+00	BCKDK NAT2
Alcohol usually taken with meals	1.11	1	0	0.0	0.00	1.0e+00	NRBF2
Nervous feelings	1.43	2	1	2.2	0.00	1.0e+00	BCKDK TP53INP2
Had menopause	2.78	4	2	4.4	-0.99	7.0e-03	LPL NRBP1 PPM1G SNX17
Forced vital capacity (FVC)	0.88	2	2	4.4	0.00	1.0e+00	BCKDK RGS12
Heel bone mineral density (BMD) T-score, automated (right)	1.40	4	2	4.4	0.54	4.6e-01	FADS3 NEIL2 RP11-380L11.3 RP11-529H2.2
Qualifications: None of the above	1.35	1	1	2.2	0.00	1.0e+00	NRBF2
Heart attack	1.93	1	0	0.0	0.00	1.0e+00	LPL
Allergy	1.40	3	1	2.2	0.00	1.0e+00	FADS3 NRBF2 RP11-373D23.3
Diabetes (self-reported)	3.10	3	1	2.2	0.00	1.0e+00	FNDC4 RP11-380L11.3 SNX17
Medication: Simvastatin	7.80	9	7	15.6	0.84	6.4e-04	APOB ATP13A1 CETP FNDC4 LPL NAT2 PAFAH1B2 USP1 ZNF259
Fluid intelligence score	1.36	1	0	0.0	0.00	1.0e+00	CGREF1
Illnesses of siblings	1.93	1	0	0.0	0.00	1.0e+00	BCKDK
Neuroticism score	1.36	2	2	4.4	0.00	1.0e+00	NEIL2 TP53INP2
Weight	2.02	11	5	11.1	-0.53	9.4e-02	APOC4 BAIAP2L2 BCKDK CKMT1A FNDC4 GRB14 MLXIPL PABPC4 RP11-373D23.3 RP11-380L11.3 TP53INP2
Impedance of arm (right)	3.11	14	10	22.2	0.27	3.2e-01	BAIAP2L2 BCKDK BCL7B CGREF1 CKMT1A FNDC4 GRB14 MLXIPL NEIL2 NRBF2 PTPN13 RP11-373D23.3 RP11-380L11.3 TP53INP2
Arm fat percentage (right)	2.03	6	4	8.9	-0.36	4.9e-01	BAIAP2L2 BCKDK GALNT2 GRB14 PABPC4 RP11-380L11.3
Trunk fat-free mass	2.49	13	6	13.3	-0.66	9.9e-03	APOC4 BCKDK BCL7B FNDC4 LCMT2 MLXIPL NRBP1 NSUN5 PPM1G PTPN13 RP11-373D23.3 RP11-380L11.3 TP53INP2
Hip circumference	2.48	11	7	15.6	-0.55	7.9e-02	BAIAP2L2 BCKDK BCL7B CKMT1A FNDC4 GRB14 MLXIPL NSUN5 RP11-373D23.3 RP11-380L11.3 TP53INP2
Alcohol intake versus 10 years previously	2.10	1	1	2.2	0.00	1.0e+00	FNDC4
Father's age at death	1.67	1	0	0.0	0.00	1.0e+00	LPL
Worrier / anxious feelings	1.33	1	1	2.2	0.00	1.0e+00	NEIL2
Number of live births	1.07	1	1	2.2	0.00	1.0e+00	FADS3
Forced expiratory volume in 1-second (FEV1)	0.89	2	1	2.2	0.00	1.0e+00	BCKDK RGS12
Pulse rate	2.34	2	2	4.4	0.00	1.0e+00	FADS3 FNDC4
Qualifications: A levels/AS levels or equivalent	1.55	2	0	0.0	0.00	1.0e+00	NRBF2 RGS12
Mouth/teeth dental problems: Dentures	1.03	1	0	0.0	0.00	1.0e+00	TP53INP2
Asthma	1.17	1	1	2.2	0.00	1.0e+00	FADS3
Medication: Cholesterol lowering	9.91	10	7	15.6	0.88	7.4e-05	APOB ATP13A1 BUD13 CETP FNDC4 LPL NAT2 PAFAH1B2 USP1 ZNF259
Forced expiratory volume in 1-second (FEV1), Best measure	1.01	2	1	2.2	0.00	1.0e+00	BCKDK RGS12
Impedance of arm (left)	3.03	13	10	22.2	0.18	5.5e-01	BAIAP2L2 BCKDK BCL7B CGREF1 FNDC4 GRB14 MLXIPL NEIL2 NRBF2 PTPN13 RP11-373D23.3 RP11-380L11.3 TP53INP2
Arm fat mass (right)	1.87	8	4	8.9	-0.33	4.3e-01	BAIAP2L2 BCKDK FNDC4 GALNT2 GRB14 PABPC4 RP11-380L11.3 TP53INP2
Trunk predicted mass	2.52	13	6	13.3	-0.66	9.7e-03	APOC4 BCKDK BCL7B FNDC4 LCMT2 MLXIPL NRBP1 NSUN5 PPM1G PTPN13 RP11-373D23.3 RP11-380L11.3 TP53INP2
Standing height	1.44	16	10	22.2	-0.58	1.9e-02	ATP13A1 BAIAP2L2 BCL7B FADS3 FNDC4 MLXIPL NRBF2 NRBP1 NSUN5 PABPC4 PPM1G RGS12 RP11-373D23.3 RP11-529H2.2 SNX17 TP53INP2
Tense / 'highly strung'	1.40	2	0	0.0	0.00	1.0e+00	BCKDK TP53INP2
Hair/balding pattern: Pattern 4	0.80	1	0	0.0	0.00	1.0e+00	FADS3
Birth weight of first child	1.88	1	0	0.0	0.00	1.0e+00	ATP13A1
Medication for cholesterol, blood pressure or diabetes	4.55	7	3	6.7	-0.80	1.7e-02	APOB BUD13 CETP FNDC4 LPL PAFAH1B2 ZNF259
Gout (self-reported)	6.33	7	5	11.1	0.97	2.3e-04	BCL7B FNDC4 INHBC MLXIPL NRBP1 PPM1G SNX17
Hypothyroidism/myxoedema (self-reported)	1.06	2	0	0.0	0.00	1.0e+00	FADS3 PTPN13
Birth weight	1.45	2	1	2.2	0.00	1.0e+00	BCL7B MLXIPL
High blood pressure (siblings)	1.98	2	0	0.0	0.00	1.0e+00	BCKDK NRBF2
Forced vital capacity (FVC), Best measure	1.07	3	2	4.4	0.00	1.0e+00	BCKDK PLTP RGS12
Body fat percentage	2.02	6	4	8.9	-0.40	4.3e-01	BAIAP2L2 BCKDK CGREF1 GALNT2 GRB14 RP11-380L11.3
Leg fat percentage (right)	1.56	6	3	6.7	-0.02	9.7e-01	BAIAP2L2 BCKDK GALNT2 GRB14 NRBF2 RP11-380L11.3
Arm fat-free mass (right)	2.63	12	7	15.6	-0.63	2.1e-02	BCKDK BCL7B CKMT1A FNDC4 LCMT2 MLXIPL NRBP1 NSUN5 PTPN13 RP11-373D23.3 RP11-380L11.3 TP53INP2
Comparative body size at age 10	1.19	2	1	2.2	0.00	1.0e+00	BCKDK TP53INP2
Worry too long after embarrassment	1.48	2	0	0.0	0.00	1.0e+00	RGS12 TP53INP2
Seen a psychiatrist for nerves, anxiety, tension or depression	1.28	1	0	0.0	0.00	1.0e+00	FADS3
Wheeze or whistling in the chest in last year	1.45	2	0	0.0	0.00	1.0e+00	BCKDK FADS3
Age at first live birth	1.56	1	0	0.0	0.00	1.0e+00	NRBF2
Qualifications: College or University degree	0.94	1	0	0.0	0.00	1.0e+00	RGS12
Medication for pain relief, constipation, heartburn	1.53	2	1	2.2	0.00	1.0e+00	ATRAID NRBP1
Angina (self-reported)	2.32	1	1	2.2	0.00	1.0e+00	LPL
Medication: Allopurinol	4.84	7	3	6.7	0.97	3.4e-04	BCL7B FNDC4 INHBC MLXIPL NRBP1 PPM1G SNX17
Whole body fat mass	1.82	7	4	8.9	-0.09	8.4e-01	BAIAP2L2 BCKDK GALNT2 GRB14 PABPC4 RP11-380L11.3 TP53INP2
Leg fat mass (right)	1.73	6	4	8.9	-0.60	2.1e-01	BAIAP2L2 BCKDK FNDC4 GRB14 RP11-373D23.3 RP11-380L11.3
Arm predicted mass (right)	2.64	11	7	15.6	-0.66	2.0e-02	BCKDK BCL7B FNDC4 LCMT2 MLXIPL NEIL2 NRBP1 NSUN5 PTPN13 RP11-373D23.3 TP53INP2
Pulse rate, automated reading	3.31	12	2	4.4	0.91	4.8e-05	C2orf28 CAD CGREF1 FADS3 FNDC4 MLXIPL NRBP1 NSUN5 PABPC4 PLTP PPM1G SNX17
Alcohol intake frequency.	3.91	8	5	11.1	0.96	1.5e-04	BCKDK C2orf28 CGREF1 FNDC4 MLXIPL NRBP1 PPM1G RGS12
Comparative height size at age 10	1.53	7	3	6.7	-0.55	2.0e-01	ATP13A1 BAIAP2L2 FNDC4 NRBP1 PPM1G RGS12 TP53INP2
Overall health rating	2.02	2	1	2.2	0.00	1.0e+00	BCKDK CGREF1
Medication: Aspirin	1.82	1	0	0.0	0.00	1.0e+00	LPL
Knee pain experienced in last month	1.26	1	0	0.0	0.00	1.0e+00	BCKDK
Hypertension (Self-reported)	1.61	3	2	4.4	0.00	1.0e+00	BCKDK NEIL2 NRBF2
Illnesses of father: Heart disease	2.74	2	0	0.0	0.96	4.0e-02	LPL RP11-380L11.3
Forced expiratory volume in 1-second (FEV1), predicted	1.23	2	1	2.2	0.00	1.0e+00	FADS3 TP53INP2
Whole body fat-free mass	2.42	13	6	13.3	-0.58	3.1e-02	APOC4 ATP13A1 BCKDK BCL7B FNDC4 LCMT2 MLXIPL NRBP1 NSUN5 PABPC4 PTPN13 RP11-373D23.3 TP53INP2
Leg fat-free mass (right)	2.28	12	7	15.6	-0.47	1.2e-01	ATP13A1 BAIAP2L2 BCKDK BCL7B FNDC4 LCMT2 MLXIPL NRBP1 PABPC4 PTPN13 RP11-373D23.3 TP53INP2
Arm fat percentage (left)	2.07	6	4	8.9	-0.37	4.7e-01	BAIAP2L2 BCKDK GALNT2 GRB14 PABPC4 RP11-380L11.3
Average weekly red wine intake	1.22	1	0	0.0	0.00	1.0e+00	NRBF2
Diabetes diagnosed by doctor	3.09	6	1	2.2	-0.85	3.0e-02	APOC1 ATP13A1 FNDC4 NRBP1 RP11-380L11.3 SNX17
Commuting to job workplace: Walk	1.04	1	0	0.0	0.00	1.0e+00	RP11-380L11.3
Medication for cholesterol	3.10	3	1	2.2	0.00	1.0e+00	FNDC4 NAT2 USP1
Medication: Laxatives (e.g. Dulcolax, Senokot)	1.72	1	0	0.0	0.00	1.0e+00	CGREF1
Back pain experienced in last month	1.20	1	0	0.0	0.00	1.0e+00	APOB
Asthma (self-reported)	1.26	1	1	2.2	0.00	1.0e+00	FADS3
Medication: Aspirin	1.78	1	0	0.0	0.00	1.0e+00	LPL
Illnesses of father: None of the above (group 1)	1.13	1	0	0.0	0.00	1.0e+00	TOMM40
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.29	1	1	2.2	0.00	1.0e+00	BCKDK
Whole body water mass	2.42	13	6	13.3	-0.58	2.9e-02	APOC4 ATP13A1 BCKDK BCL7B FNDC4 LCMT2 MLXIPL NRBP1 NSUN5 PABPC4 PTPN13 RP11-373D23.3 TP53INP2
Leg predicted mass (right)	2.29	12	7	15.6	-0.49	9.1e-02	ATP13A1 BAIAP2L2 BCKDK BCL7B FNDC4 LCMT2 MLXIPL NRBP1 PABPC4 PTPN13 RP11-373D23.3 TP53INP2
Arm fat mass (left)	1.86	9	4	8.9	-0.32	4.0e-01	BAIAP2L2 BCKDK CKMT1A FNDC4 GALNT2 GRB14 PABPC4 RP11-380L11.3 TP53INP2
Number of self-reported non-cancer illnesses	2.28	1	1	2.2	0.00	1.0e+00	FNDC4
Average weekly champagne plus white wine intake	1.23	1	0	0.0	0.00	1.0e+00	FADS3
Miserableness	1.27	1	0	0.0	0.00	1.0e+00	NEIL2
Medication: Blood pressure	1.80	1	0	0.0	0.00	1.0e+00	NEIL2
High cholesterol (Self-reported)	16.82	22	13	28.9	0.87	1.1e-08	APOB ATP13A1 BCKDK BCL7B BUD13 C2orf28 CAD CGREF1 FNDC4 HS1BP3 LPL MLXIPL NAT2 NRBP1 PAFAH1B2 PCSK7 PPM1G RGS12 SIDT2 SNX17 USP1 ZNF259
Medication: Bendroflumethiazide	1.41	1	0	0.0	0.00	1.0e+00	NEIL2
Medication: Atorvastatin	7.94	11	4	8.9	0.94	1.3e-06	APOB ATP13A1 BCKDK BUD13 FNDC4 LPL NRBP1 PAFAH1B2 PPM1G USP1 ZNF259
Basal metabolic rate	2.28	14	5	11.1	-0.55	3.3e-02	APOC4 ATP13A1 BCKDK BCL7B CKMT1A FNDC4 LCMT2 MLXIPL NRBP1 NSUN5 PABPC4 PTPN13 RP11-373D23.3 TP53INP2
Leg fat percentage (left)	1.54	6	3	6.7	0.02	9.7e-01	BAIAP2L2 BCKDK GALNT2 GRB14 NRBF2 RP11-380L11.3
Arm fat-free mass (left)	2.40	11	6	13.3	-0.63	2.8e-02	BCKDK BCL7B CKMT1A FNDC4 LCMT2 MLXIPL NEIL2 NRBP1 PTPN13 RP11-373D23.3 TP53INP2
Average weekly beer plus cider intake	0.96	1	1	2.2	0.00	1.0e+00	NRBF2
Irritability	2.19	5	2	4.4	-0.27	6.6e-01	ATP13A1 BCKDK FADS3 NEIL2 TP53INP2
Diastolic blood pressure, automated reading	1.33	3	3	6.7	0.00	1.0e+00	BCKDK NEIL2 NRBF2
Vascular/heart problems diagnosed by doctor	1.80	4	1	2.2	-0.58	4.2e-01	BCKDK NAT2 NEIL2 NRBF2
Cholesterol lowering medication	9.51	12	6	13.3	0.82	1.9e-04	APOB BCKDK BUD13 FNDC4 LPL NAT2 PAFAH1B2 PCSK7 RP11-380L11.3 SIDT2 USP1 ZNF259
Pain experienced in last month	1.17	2	0	0.0	0.00	1.0e+00	BCKDK PABPC4
Basal cell carcinoma (self-reported)	1.19	1	0	0.0	0.00	1.0e+00	TP53INP2
Heart attack/myocardial infarction (self-reported)	2.04	1	0	0.0	0.00	1.0e+00	LPL
Impedance of whole body	2.39	14	9	20.0	0.22	4.4e-01	BAIAP2L2 BCKDK BCL7B CKMT1A FNDC4 GRB14 LCMT2 MLXIPL NEIL2 NRBF2 PTPN13 RP11-380L11.3 TP53INP2 ZNF513
Leg fat mass (left)	1.77	6	4	8.9	-0.60	2.0e-01	BAIAP2L2 BCKDK FNDC4 GRB14 RP11-373D23.3 RP11-380L11.3
Arm predicted mass (left)	2.46	12	6	13.3	-0.66	1.5e-02	APOC4 BCKDK BCL7B FNDC4 LCMT2 MLXIPL NEIL2 NRBP1 NSUN5 PTPN13 RP11-373D23.3 TP53INP2

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	7	0.206	1.7
GTEx	Adipose Visceral Omentum	10	0.505	2.1
GTEx	Adrenal Gland	5	0.351	1.5
GTEx	Artery Aorta	9	0.311	1.7
GTEx	Artery Coronary	4	0.346	1.7
GTEx	Artery Tibial	17	0.467	1.7
GTEx	Brain Caudate basal ganglia	1	0.111	1.4
GTEx	Brain Cerebellar Hemisphere	5	0.344	1.5
GTEx	Brain Cerebellum	6	0.311	1.7
GTEx	Brain Cortex	3	0.298	1.6
GTEx	Brain Frontal Cortex BA9	2	0.222	1.4
GTEx	Brain Hippocampus	1	0.196	1.5
GTEx	Brain Hypothalamus	0	0.000	1.4
GTEx	Brain Nucleus accumbens basal ganglia	1	0.118	1.5
GTEx	Brain Putamen basal ganglia	1	0.165	1.5
GTEx	Breast Mammary Tissue	4	0.209	1.5
GTEx	Breast Mammary Tissue (Male)	1	0.086	1.5
GTEx	Breast Mammary Tissue (Female)	8	0.507	1.6
GTEx	Cells EBV-transformed lymphocytes	3	0.217	1.7
GTEx	Cells Transformed fibroblasts	16	0.391	1.9
GTEx	Colon Sigmoid	5	0.350	1.7
GTEx	Colon Transverse	3	0.150	1.6
GTEx	Esophagus Gastroesophageal Junction	4	0.286	1.9
GTEx	Esophagus Mucosa	11	0.340	1.7
GTEx	Esophagus Muscularis	10	0.318	1.6
GTEx	Heart Atrial Appendage	4	0.259	1.6
GTEx	Heart Left Ventricle	4	0.270	1.6
GTEx	Liver	3	0.431	1.6
GTEx	Lung	9	0.322	1.7
GTEx	Muscle Skeletal	7	0.249	1.6
GTEx	Nerve Tibial	10	0.238	1.7
GTEx	Ovary	2	0.226	1.9
GTEx	Pancreas	3	0.188	1.7
GTEx	Pituitary	1	0.091	1.6
GTEx	Prostate	3	0.369	1.7
GTEx	Skin Not Sun Exposed Suprapubic	7	0.292	1.8
GTEx	Skin Sun Exposed Lower leg	10	0.283	1.8
GTEx	Small Intestine Terminal Ileum	0	0.000	1.5
GTEx	Spleen	5	0.362	1.7
GTEx	Stomach	3	0.211	1.7
GTEx	Testis	8	0.260	1.9
GTEx	Thyroid	17	0.439	1.8
GTEx	Uterus	1	0.180	1.5
GTEx	Vagina	1	0.162	2.0
GTEx	Whole Blood	13	0.674	1.9
METSIM	Adipose	17	0.376	1.8
NTR	Blood	11	0.462	1.7
ROSMAP	Brain Pre-frontal Cortex	17	0.397	1.8
YFS	Blood	18	0.394	1.7
CommonMind	Brain Pre-frontal Cortex	16	0.303	1.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	7	0.452	1.8
The Cancer Genome Atlas	Breast Invasive Carcinoma	16	0.386	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	4	0.386	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	8	0.415	1.8
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.154	1.5
The Cancer Genome Atlas	Glioblastoma Multiforme	9	0.932	1.9
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	10	0.389	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	20	0.517	1.8
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	8	0.413	2.0
The Cancer Genome Atlas	Brain Lower Grade Glioma	12	0.296	1.6
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	6	0.575	2.2
The Cancer Genome Atlas	Lung Adenocarcinoma	10	0.361	1.6
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	9	0.381	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	7	0.469	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	4	0.254	1.5
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.239	1.5
The Cancer Genome Atlas	Prostate Adenocarcinoma	16	0.366	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.308	1.4
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.303	1.5
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.202	1.6
The Cancer Genome Atlas	Stomach Adenocarcinoma	3	0.189	1.5
The Cancer Genome Atlas	Testicular Germ Cell Tumors	3	0.251	1.5
The Cancer Genome Atlas	Thyroid Carcinoma	19	0.390	1.7
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.207	1.5